Another way to look at this hypothesis, imo, is that as of March 6, 2024, NWBO would have known they would need at least (150 days or perhaps even 210 days) + the (365 days extension guidance including 3 RFIs (published April 3, 2025)), to get to the window of August 3 to October 1, 2025 because, they knew the Survaxm primary reporting date was August 18, 2025 and the last randomized Survaxm patient would also only be followed through that time according to the protocol. If Survaxm heads up to results came in early, as it appears they did on July 16, 2025, the August 3 date can make things a sliver faster, or NWBO still may need actual Survaxm primary reporting first, leaving that MHRA max buffer to October 1. Just my hypothesis.
That ain’t no way to treat an investor.
Market Data 
Markets 
